Chinese private equity firm Centurium Capital is reportedly exploring the possibility of selling its stake in Taibang Biologic, a biotechnology company based in China. The move signals potential changes in the company’s ownership structure, though no official sale has been confirmed at this time.
Centurium Capital, which has been involved in various investments across the healthcare and technology sectors, acquired its stake in Taibang Biologic as part of its strategic portfolio. The company’s decision to consider divestment may reflect broader shifts within the private equity firm’s investment strategy or changes in the biotech sector.
It is not yet clear whether a sale will proceed or if other investors will enter the picture. Taibang Biologic, which specializes in biopharmaceuticals and regenerative medicine, has been focusing on developing innovative treatments, attracting attention from both domestic and international markets.
As the situation develops, industry analysts will be watching to see how this potential divestment might impact Taibang Biologic’s future operations and its position in China’s biotech landscape. Both parties have declined to comment publicly on the matter.